An open-label, randomized, single-dose, two-period, two-treatment crossover bioavailability study comparing 5 mg/0.5 ml of intramuscular naloxone hydrochloride to 2 mg/0.4 ml intramuscular naloxone hydrochloride autoinjector in healthy subjects.
Latest Information Update: 03 Jun 2020
At a glance
- Drugs Naloxone (Primary)
- Indications Opioid-related disorders
- Focus Pharmacokinetics
- Sponsors Adamis Pharmaceuticals Corporation
Most Recent Events
- 03 Jun 2020 New trial record
- 27 May 2020 According to an Adamis Pharmaceuticals Corporation Media Release, data from this trial was published in The Journal of Opioid Management
- 27 May 2020 Results published in Adamis Pharmaceuticals Corporation Media Release.